- Trial phase
- Phase 2
- Time to market
- agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
- Why 5/10
- The next hard, dated catalyst is U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, but topline data is not expected until 2H2027, which is more than 12 months away. With no PDUFA date or pivotal readout imminent, the impact score is capped at 5. The drug is the company's lead asset and drives most of the thesis, but the defining binary (Phase 2 ARDS readout) is too distant to score higher.
The next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.
Price Chart
Executive Summary
agenT-797 is MiNK Therapeutics' lead asset, an off-the-shelf (allogeneic) iNKT cell therapy being developed for both cancer and inflammatory conditions. The drug is in Phase 2 trials for acute lung injury/ARDS (randomized trial C-1300-02), MSS metastatic colorectal cancer, and PD-1 refractory gastroesophageal cancer. In Q3 2026, MiNK generated its first pre-commercial product revenue ($0.2M) from a named-patient access program in Brazil, and the drug was selected for the ARPA-H BoSS program (up to $87M in program-wide funding). The company has strong analyst support (mean price target $44 vs $10.22 current price) but faces a long catalyst timeline with ARDS trial data not expected until 2H2027 and a limited cash runway of $7.5M that may require near-term financing.
How It Works
agenT-797 is an off-the-shelf (allogeneic) cell therapy made from a specific type of immune cell called invariant Natural Killer T (iNKT) cells. These cells are donated from healthy individuals and can be given to any patient without needing to match tissue types. Once infused, iNKT cells act as immune system regulators: in cancer, they switch to a pro-inflammatory state to help kill tumor cells, while in acute lung injury/ARDS, they shift to an anti-inflammatory state to reduce tissue damage and promote healing. This context-dependent behavior means the same manufactured cell product can potentially treat both cancer and inflammatory conditions.
Trial Status
agenT-797 is being evaluated in multiple Phase 2 trials: (1) C-1300-02, a randomized Phase 2 trial in acute lung injury/ARDS, is enrolling patients in Ukraine with U.S. sites opening and dosing expected before year-end 2026; (2) a Phase 2 trial in MSS metastatic colorectal cancer with liver metastases (NCT07550088) in combination with botensilimab/balstilimab at Scripps; (3) a Phase 2 trial in PD-1 refractory gastroesophageal cancer, where data presented at AACR 2026 showed a 77% disease control rate. Early Phase 2 data in severe hypoxemic pneumonia presented at MHSRS in August 2026 showed all treated patients alive and afebrile at Day 28 with improved oxygenation. Preclinical data at SITC 2026 showed tumor-cell killing in checkpoint inhibitor-resistant colorectal cancer models.
The Two-Sided Case
Upcoming Catalysts
- U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026
- Topline data from the randomized Phase 2 ARDS trial expected in 2H2027
- Potential ARPA-H BoSS program funding allocation updates
- Enrollment updates from the Phase 2 MSS colorectal cancer trial (NCT07550088)
- Additional data presentations at medical conferences in 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MiNK Therapeutics PRESS-RELEASE INKT ·Originating report